Drug mechanisms in anxiety

Current Opinion in Investigational Drugs

Volumn 2, Issue 2, 2001, Pages 259-265

  Bourin, M ^a   Hascoet M ^a  

^a UNIVERSITÉ DE NANTES   (France)

Author keywords

5 HT; Anxiety; Benzodiazepines; Cholecystokinin; Corticotrophin releasing factor

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; 1 (2,3 DIHYDRO 1 METHYL 2 OXO 5 PHENYL 1H 1,4 BENZODIAZEPIN 3 YL) 3 (3 METHYLPHENYL)UREA; 1 [3 FLUORO 5 (3 PYRIDYL)PHENYLCARBAMOYL] 5 METHOXY 6 TRIFLUOROMETHYLINDOLINE; 2 (6 CHLORO 5 FLUORO 1 INDOLYL) 1 METHYLETHYLAMINE; 2 [N (2 BROMO 4 ISOPROPYLPHENYL) N ETHYLAMINO] 4 [4 (3 FLUOROPHENYL) 1,2,3,6 TETRAHYDRO 1 PYRIDINYL] 6 METHYLPYRIMIDINE; 4 [4 (3 FLUOROPHENYL) 1,2,3,6 TETRAHYDRO 1 PYRIDINYL] 2 [N ETHYL N (4 ISOPROPYL 2 METHYLTHIOPHENYL)AMINO] 6 METHYLPYRIMIDINE; 4 [[2 [2 [[(2 ADAMANTYLOXY)CARBONYL]AMINO] 3 (1H INDOL 3 YL) 2 METHYLPROPIONAMIDO] 1 PHENYLETHYL]AMINO] 4 OXOBUTYRIC ACID MEGLUMINE; 4 AMINOBUTYRIC ACID A RECEPTOR; 5 METHYL 1 [[2 [(2 METHYL 3 PYRIDYL)OXY] 5 PYRIDYL]CARBAMOYL] 6 TRIFLUOROMETHYLINDOLINE; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; BUSPIRONE; CHOLECYSTOKININ RECEPTOR BLOCKING AGENT; CITALOPRAM; COLYKADE; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; CRA 0165; EGLUMETAD; FLUOXETINE; GLUTAMIC ACID; LEUCYLSERYLALANYLLEUCINE; LORGLUMIDE; MEMANTINE; METABOTROPIC RECEPTOR; METABOTROPIC RECEPTOR ANTAGONIST; N (4 BROMOPHENYL) 3 OXO 4,5 DIPHENYL 1 PYRAZOLIDINECARBOXAMIDE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PD 135158; SEROTONIN 1A RECEPTOR; SEROTONIN 1B RECEPTOR; SEROTONIN 2C ANTAGONIST; SEROTONIN 2C RECEPTOR; SEROTONIN ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AMINO ACID TRANSPORT; ANXIETY NEUROSIS; CLINICAL TRIAL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DEPENDENCE; DRUG EFFECT; DRUG MECHANISM; DRUG PENETRATION; DRUG SCREENING; DRUG STRUCTURE; DRUG TARGETING; GABAERGIC SYSTEM; HUMAN; LIGAND BINDING; NEUROTRANSMISSION; NONHUMAN; PANIC; RECEPTOR DOWN REGULATION; REVIEW; SIDE EFFECT; TRANQUILIZING ACTIVITY; TREATMENT OUTCOME;

ANIMALS; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; ANXIETY; CHOLECYSTOKININ; GAMMA-AMINOBUTYRIC ACID; GLUTAMIC ACID; HUMANS; SEROTONIN;

EID: 0035110503     PISSN: 09678298     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (59)

1. Clinical methodology for testing of anxiolytic drugs
2. GABA A receptor alpha-subunit is an essential prerequisite for receptor formation in vivo
3. GABA A receptors: Structural requirements and sites of gene expression in mammalian brain
4. Genetic inactivation of the serotonin (1A) receptor in mice results in down regulation of major GABA(A) receptor alpha subunits, reduction GABA(A) receptor binding, and benzodiazepine-resistant anxiety
5. Anxiolytic 2,3-benzodiazepines, their specific binding to the basal ganglia
6. The anxiolytic-like properties of two selective MAOIs, moclobemide and selegiline, in a standard and an enhanced light/dark aversion test
7. Anxiolytic-like effects of antidepressants after acute administration in a four-plate test in mice
8. Behavioral effects of acute and chronic imipramine in the elevated T-maze model of anxiety
9. Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone, and diazepam
10. Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder
11. Decrease in brain serotonin 2 receptor binding in patients with major depression following desipramine treatment: A positron emission tomography study with fluorine-18-labeled setoperone
12. Antisense inhibition of 5-hydroxytryptamine 2A receptor induces an antidepressant-like effect in mice
13. Nitric oxide synthase inhibitors have antidepressant-like properties in mice. 2. Chronic treatment results in downregulation of cortical beta-adrenoceptors
14. Glutamate in CNS disorders as a target for drug development: An update
15. Glutamate in CNS disorders
16. Potential anti-anxiety, anti-addictive effects of LY 354740, a selective group II glutamate metabotropic receptor agonist in animal models
17. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist - A review of preclinical data
18. Anxiolytic and anxiogenic drugs: Changes in behaviour and endocrine responses
19. Chlordiazepoxide attenuates response suppression induced by corticotrophin-releasing factor in the conflict test
20. 4-(1,3-dimethoxyprop-2-ylamino)-2,7-dimethyl-8-(2,4-dichlorophenyl)pyrazo lol [1,5-a]-1,3,5-triazine: A potent, orally bioavailable CRF(1) receptor antagonist
21. The discovery of 4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-mothoxyphenyl)-pyrazolo-[1,5-a]-pyr imidine: A corticotropin-releasing factor (hCRF1) antagonist
22. A role for corticotropin releasing factor and urocortin in behavioral responses to stressors
23. Receptor binding, behavioral and electrophysiological profiles of non peptide corticotropin-releasing factor subtype 1 receptor antagonists CRA1000 and CRA1001
24. Further analysis of the effects of cholecystokinin octapeptide on avoidance behavior in rats
25. CCK-octapeptide injected in CSF causes satiety in sheep
26. Cholecystokinin, motilin and secretin effects on the central nervous system
27. Anxiogenic effect of cholecystokinin in rats
28. Anxiogenic-like action of caerulein, a CCK-8 receptor agonist, in the mouse: Influence of acute and subchronic diazepam treatment
29. Evidence that CCK-B receptors mediate the regulation of exploratory behaviour in the rat
30. The behavioural properties of CI-988, a selective cholecystokinin B receptor antagonist
31. 2 agonists
32. Role of endogenous corticotropin-releasing factor in mediation of neuroendocrine and behavioral responses to cholecystokinin octapeptide sulfate ester in rats
33. Effects of Boc CCK-4 and L-365,260 on cortical 5-HT release in guinea-pigs on exposure to elevated plus maze
34. Two faces of cholecystokinin: Anxiety and schizophrenia
35. CCK receptor antagonists in animal models of anxiety: Comparison between exploration tests, conflict procedures and a model based on defensive behaviours
36. Imipramine antagonizes the panicogenic effects of CCK-4 in panic disorder patients
37. The panicogenic effects of cholecystokinin tetrapeptide are antagonized by L-365,260, a central cholecytokinin receptor antagonist, in patients with panic disorder
38. Cholecystokinin and panic disorder
39. Placebo-controlled trial of the CCK-B antagonist, CI-988, in panic disorder
40. A placebo-controlled trial of L-365,260, a CCK-B antagonist, in panic disorder
41. Human pharmacokinetics and tolerability of L-365,260, a novel cholecystokinin-B antagonist
42. Improved oral absorption of L-365,260, a poorly soluble drug
43. Effects of the CCK(B) antagonist Cl-988 on responses to mCPP in generalized anxiety disorder
44. 5-Hydroxytryptamine receptors
45. VII. International union of pharmacology classification of receptors for 5-hydroxytryptamine (serotonin)
46. 1B receptors
47. 5-HT-moduline controls serotonergic activity: Implication in neuroimmune reciprocal regulation mechanisms
48. 1B receptors in rat central nervous system: Role of 5-HT-Moduline
49. 1C receptors in the choroid plexus
50. 1C receptor antagonists
51. 3H]mesulergine binding in human brain postmortem
52. 2C receptor agonist, in three animal models of anxiety
53. 2C receptor inverse agonists: Identification of 5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]-5-pyridyl]carbamoyl]-6-trifluoromethyli ndoline (SB-243213) as a potential antidepressant/anxiolytic agent
54. 2C receptor down regulation
55. 3H]D-aspartate release by deramciclane
56. Affinities of the two enantiomers of fluoxetine for subtypes of serotonin receptors
57. 2C receptors
58. 1 receptor in the brain: Pharmacology and putative functions
59. 1 receptor antagonist, has an anxiolytic action in the social interaction test in rats